论文部分内容阅读
目的:比较吡柔比星两种膀胱内灌注方法预防表浅性膀胱癌术后复发的有效性及安全性。方法:将52例经尿道膀胱癌电切术后表浅性膀胱癌患者随机分为两组。每次吡柔比星灌注剂量30 mg,治疗组术后24 h内膀胱灌注1次,此后每周灌注1次,连续8周,再改为每月灌注1次,至术后1年。对照组术后2周开始灌注,此后每周灌注1次,连续8周,再改为每月灌注1次,至术后1年。结果:全部病例均获随访,时间为12～24个月,平均随访16.3个月。其中治疗组随访期内2例复发,复发率8%;对照组随访期内4例复发,复发率14%,两组复发率比较差异有统计学意义(P<0.05),不良反应主要为尿路刺激症状。结论:本研究显示,吡柔比星膀胱灌注预防表浅性膀胱癌术后复发的疗效满意,用药方便,患者耐受性好;术后即刻膀胱灌注联合常规灌注较常规灌注可以降低肿瘤复发率,值得推荐。
Objective: To compare the efficacy and safety of two intravesical instillation methods of pirarubicin in preventing postoperative recurrence of superficial bladder cancer. Methods: 52 cases of superficial bladder cancer after transurethral resection of bladder cancer were randomly divided into two groups. Each dose of pirarubicin 30 mg intravesical instillation within 24 h after the treatment group perfusion once a week for 8 weeks and then once a month to 1 year after surgery. The control group began perfusion at 2 weeks after operation, then perfusion once a week for 8 weeks and then once a month to 1 year after operation. Results: All patients were followed up for 12-24 months with an average follow-up of 16.3 months. The recurrence rate was 8% in 2 cases during the follow-up period in the treatment group, 4 cases were recurrence and the recurrence rate was 14% in the control group, the recurrence rate was significantly different between the two groups (P <0.05), and the main adverse reactions were urine Road irritation symptoms. CONCLUSIONS: This study showed that pirarubicin was effective in preventing postoperative recurrence of superficial bladder cancer with convenient curative effect and good patient tolerance. Intravesical instillation combined with conventional perfusion could reduce the recurrence rate after routine operation ,Recommended.